Skip to main content
    T

    Teva Pharma Industries Ltd ADR (TEVA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $42.58
    -1.92 (-4.31%)

    Market Cap: $51.92B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Teva Pharma Industries Ltd ADR (TEVA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Teva Pharma Industries Ltd ADR reported revenue of $17.26B for the fiscal year ended Dec 31, 2025, up 4.3% from the year before. That year, net income was $1.41B with a net margin of 8.2%, operating cash flow was $1.65B and free cash flow was $1.15B. The quarter ended Sep 30, 2026 had revenue of $4.39B and net income of $233.00M.

    Revenue and Margins

    The operating margin was 12.5% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue fell from $21.90B, a compound annual decline of 2.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$17.26B+4.3%51.8%12.5%8.2%
    Dec 2024$16.54B+4.4%48.7%-1.8%-9.9%
    Dec 2023$15.85B+6.2%48.2%2.7%-3.5%
    Dec 2022$14.93B-6.0%46.7%-14.7%-16.4%
    Dec 2021$15.88B-4.7%47.8%10.8%2.6%
    Dec 2020$16.66B-1.4%46.4%-21.4%-24.0%
    Dec 2019$16.89B-10.4%44.6%-2.6%-5.9%
    Dec 2018$18.85B-15.8%44.0%-8.7%-11.4%
    Dec 2017$22.39B+2.2%48.4%-78.1%-72.7%
    Dec 2016$21.90BN/A54.1%9.8%1.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 46.2% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$17.26B$16.54B$15.85B$14.93B$15.88B$16.66B$16.89B$18.85B$22.39B$21.90B
    Cost of revenue$8.32B$8.48B$8.20B$7.95B$8.28B$8.93B$9.35B$10.56B$11.56B$10.04B
    Gross profit$8.94B$8.06B$7.64B$6.97B$7.59B$7.73B$7.54B$8.30B$10.82B$11.86B
    Research and development$1.01B$1.05B$953.00M$838.00M$1.09B$1.79B$1.01B$1.21B$1.85B$2.11B
    Operating income$2.16B-$303.00M$433.00M-$2.20B$1.72B-$3.57B-$443.00M-$1.64B-$17.48B$2.15B
    Net income$1.41B-$1.64B-$559.00M-$2.45B$417.00M-$3.99B-$999.00M-$2.15B-$16.27B$329.00M
    EBITDA$3.14B$4.43B$433.00M-$925.00M$4.41B$4.61B$4.44B$186.00M-$15.48B$2.90B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$4.39B$4.14B$3.98B$4.71B$4.48B$4.18B$3.89B$4.23B$4.33B$4.16B$3.82B$4.46B
    Gross profit$2.44B$2.15B$1.97B$2.66B$2.30B$2.10B$1.88B$2.12B$2.15B$2.02B$1.77B$2.42B
    Operating income$714.00M$149.00M$652.00M$300.00M$882.00M$455.00M$519.00M-$29.00M-$51.00M-$5.00M-$218.00M$756.00M
    Net income$233.00M-$576.00M$369.00M$480.00M$433.00M$282.00M$214.00M-$217.00M-$437.00M-$846.00M-$139.00M$463.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $16.81B exceeded cash and equivalents by $13.25B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$40.75B$39.33B$43.48B$44.01B$47.67B$50.64B$57.47B$60.68B$70.61B$92.89B
    Current assets$13.95B$12.55B$12.48B$12.05B$12.57B$13.01B$13.46B$13.79B$15.38B$16.96B
    Cash and equivalents$3.56B$3.30B$3.23B$2.80B$2.17B$2.18B$1.98B$1.78B$963.00M$988.00M
    Total liabilities$32.83B$33.61B$35.35B$35.41B$36.42B$39.58B$42.41B$44.89B$51.87B$57.90B
    Short-term debt$1.82B$1.78B$1.67B$2.11B$1.43B$3.19B$2.35B$2.22B$3.65B$3.28B
    Long-term debt$14.99B$16.00B$18.16B$19.10B$21.62B$22.73B$24.56B$26.70B$28.83B$32.52B
    Shareholder equity$7.91B$5.37B$7.51B$7.80B$10.28B$10.03B$13.97B$14.71B$17.36B$33.34B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$40.04B$39.86B$40.04B$40.75B$39.86B$40.13B$38.41B$39.33B$41.76B$41.34B$42.77B$43.48B
    Total liabilities$32.06B$32.10B$31.81B$32.84B$32.60B$33.30B$32.15B$33.61B$35.37B$34.77B$35.23B$35.35B
    Cash and equivalents$4.08B$3.65B$3.74B$3.56B$2.20B$2.16B$1.70B$3.30B$3.32B$2.26B$2.99B$3.23B
    Shareholder equity$7.98B$7.76B$8.23B$7.91B$7.25B$6.83B$6.26B$5.37B$6.07B$6.36B$7.28B$7.51B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 69.7% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.65B$1.25B$1.37B$1.59B$798.00M$1.22B$538.00M$2.45B$3.51B$5.22B
    Capital expenditures$501.00M$498.00M$526.00M$548.00M$562.00M$578.00M$119.00M$651.00M$874.00M$901.00M
    Free cash flow$1.15B$749.00M$842.00M$1.04B$236.00M$638.00M$419.00M$1.79B$2.63B$4.32B
    Dividends paidN/AN/AN/AN/AN/AN/A$52.00M$22.00M$1.16B$1.56B
    Investing cash flow$737.00M$792.00M$968.00M$656.00M$1.52B$863.00M$1.35B$1.87B$2.16B-$35.74B
    Financing cash flow-$2.15B-$1.79B-$1.91B-$1.49B-$2.17B-$1.89B-$241.00M-$3.35B-$5.75B$25.22B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$241.00M$411.00M-$40.00M$1.16B$369.00M$227.00M-$105.00M$575.00M$693.00M$103.00M-$124.00M$1.18B
    Capital expenditures$120.00M$104.00M$168.00M$142.00M$136.00M$96.00M$127.00M$129.00M$148.00M$97.00M$124.00M$119.00M
    Free cash flow$121.00M$307.00M-$208.00M$1.02B$233.00M$131.00M-$232.00M$446.00M$545.00M$6.00M-$248.00M$1.06B
    Last 12 quarters

    Frequently Asked Questions About TEVA

    What is Teva Pharma Industries Ltd ADR's annual revenue?

    Teva Pharma Industries Ltd ADR reported revenue of $17.26B for the fiscal year ended Dec 31, 2025.

    How fast is Teva Pharma Industries Ltd ADR's revenue growing?

    Revenue was up 4.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.0%.

    Is Teva Pharma Industries Ltd ADR profitable?

    Yes. Teva Pharma Industries Ltd ADR reported net income of $1.41B for the fiscal year ended Dec 31, 2025, with a net margin of 8.2%.

    How much free cash flow does TEVA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.65B minus capital expenditures of $501.00M produced free cash flow of $1.15B.

    How much debt does Teva Pharma Industries Ltd ADR have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $14.99B, short-term debt of $1.82B and cash and equivalents of $3.56B.